Drugs / Afimetoran
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT05866627 | Jul → Sep 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05901714 | Jun 2023 → Apr 2024 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04941755 | Jun → Sep 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04493541 | Aug 2020 → Apr 2023 | cutaneous lupus erythematosus | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04470778 | Jul 2020 → Mar 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04269356 | Feb 2020 → Mar 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04016753 | Aug 2019 → Feb 2020 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04039373 | Jul → Sep 2019 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03950960 | May → Jul 2019 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03634995 | Aug 2018 → Oct 2019 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04895696 | Oct 2021 → Jun 2026 overdue | systemic lupus erythematosus | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Afimetoran | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04895696 ↗ |
| Known as | BMS-986256 | “An Open-label, Single-sequence, Drug-drug Interaction Study in Healthy Participants to Assess the Effect of Phenytoin on the Pharmacokinetics of a Single Oral Dose of...” NCT05901714 ↗ |
| Action | Inhibit | “Toll-like receptor 7 inhibitor” CHEMBL4650329 ↗1“Toll-like receptor 8 inhibitor” CHEMBL4650329 ↗ |
| Modality | Small molecule | — CHEMBL4650329 ↗ |
| Target | TLR7 | “Toll-like receptor 7 inhibitor” CHEMBL4650329 ↗ |
| Target | TLR8 | “Toll-like receptor 8 inhibitor” CHEMBL4650329 ↗ |